MRI characteristics of intralabyrinthine schwannoma on post-contrast 4 h-delayed 3D-FLAIR imaging.


Journal

Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 27 07 2021
revised: 25 09 2021
accepted: 29 09 2021
pubmed: 25 10 2021
medline: 3 3 2022
entrez: 24 10 2021
Statut: ppublish

Résumé

The purpose of this study was to describe the MRI characteristics of intralabyrinthine schwannoma (ILS) on post contrast three-dimensional (3D) fluid-attenuation-inversion-recovery (FLAIR) images obtained four hours after intravenous administration of a gadolinium-based contrast agent (4h-3D-FLAIR). This IRB-approved retrospective multi-center study included patients presenting with typical ILS from January 2016 to October 2020. All medical charts were systematically collected. All MRI examinations, including 4h-3D-FLAIR images, were reviewed by two board-certified neuroradiologists. Main outcome measures were location, signal intensity and associated anomalies of ILS. Twenty-seven out of 8730 patients (0.31%) referred for the investigation of a cochleovestibular disorder had a final diagnosis of ILS. There were 13 men and 14 women with a mean age of 52 ± 17 (SD) years (age range: 20-86 years). The most common clinical presentation was unilateral progressive sensorineural hearing loss (16/27; 59%). All ILS were unilateral and 15 (15/27; 55%) were intracochlear. All ILS presented as a hypointense filling defect within the labyrinth on T2-weighted images that enhanced on post-contrast T1-weighted images. On 4h-3D-FLAIR images, all ILS presented as a hypointense filling defect, associated with diffuse perilymphatic hyperintensity. Two patients (2/27; 7%) presented with ipsilateral endolymphatic hydrops. ILS displays consistent features on post-contrast 4h-3D-FLAIR images. ILS should not be confused with endolymphatic hydrops and requires a systematic analysis of the corresponding T2-weighted images.

Identifiants

pubmed: 34688591
pii: S2211-5684(21)00224-2
doi: 10.1016/j.diii.2021.09.011
pii:
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-176

Informations de copyright

Copyright © 2021 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Auteurs

Guillaume Poillon (G)

Department of Neuroradiology, Fondation Adolphe de Rothschild Hospital, Paris 75019, France. Electronic address: gpoillon@for.paris.

Julien Horion (J)

Department of Neuroradiology, Rouen University Hospital, Rouen 7600, France.

Mary Daval (M)

Department of Head and Neck Surgery, Fondation Adolphe de Rothschild Hospital, Paris 75019, France.

Didier Bouccara (D)

Department of Head and Neck Surgery, Georges Pompidou Hospital, AP-HP, Paris 75015, France.

Charlotte Hautefort (C)

Department of Head and Neck Surgery, Lariboisière University Hospital, AP-HP, Paris 75010, France.

Juliette Housset (J)

Department of Head and Neck Surgery, Lariboisière University Hospital, AP-HP, Paris 75010, France.

Daniel Levy (D)

Department of Head and Neck Surgery, Fondation Adolphe de Rothschild Hospital, Paris 75019, France.

Yvonne Purcell (Y)

Department of Neuroradiology, Fondation Adolphe de Rothschild Hospital, Paris 75019, France.

Julien Savatovsky (J)

Department of Neuroradiology, Fondation Adolphe de Rothschild Hospital, Paris 75019, France.

Michel Toupet (M)

Centre d'Explorations Fonctionnelles Otoneurologiques, Paris 75015, France.

Arnaud Attyé (A)

Department of Neuroradiology, Grenoble University Hospital, Grenoble 38000, France.

Michael Eliezer (M)

Department of Neuroradiology, Lariboisière University Hospital, AP-HP, Paris 75010, France; Université de Paris, Faculté de Médecine, Paris 75010, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH